Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT00744185
PHASE2/PHASE3

Propranolol in Capillary Hemangiomas

Sponsor: University Hospital, Bordeaux

View on ClinicalTrials.gov

Summary

The investigators observed that Propranolol, a beta-blocker commonly used in children was efficient to control the growth of alarming hemangiomas of the face. The primary objective of this study is to determine the efficiency of 1 month-early treatment of propranolol in infants aged less than 4 months affected by an hemangioma without any consequences on vital or functional structure and not justifying corticosteroids. The secondary objectives are: * the kinetic of the hemangioma evolution in infants treated by propranolol * Observance * Safety

Official title: Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas

Key Details

Gender

All

Age Range

Any - 4 Months

Study Type

INTERVENTIONAL

Enrollment

14

Start Date

2008-10

Completion Date

2010-04

Last Updated

2026-06-01

Healthy Volunteers

No

Interventions

DRUG

propranolol treatment

30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days

DRUG

placebo treatment

30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days

Locations (1)

Dermatologie Pédiatrique

Bordeaux, France